Genprexincis A Clinical Stage Gene Therapy Company Based In Austintexasfounded In 2009The Company Focuses On Developing Innovative Therapies For Cancer And Diabetesutilizing Advanced Gene Therapy Technologies To Meet Significant Medical Needs In These Areas Genprex S Key Offerings Include The Oncoprex Delivery Systema Non Viral Platform Designed For Targeted Gene Delivery To Cancer Cellsand Aav Vector Technologywhich Delivers Genes Directly To The Pancreas For Diabetes Treatmentthe Company S Product Pipeline Features Reqorsacurrently In Clinical Trials For Non Small Cell Lung Cancer And Small Cell Lung Cancerand Gpx 002A Preclinical Therapy Aimed At Reprogramming Pancreatic Cells For Diabetes Management With A Market Capitalization Of $34 2 Million And A Dedicated Team Of 26 Employeesgenprex Is Committed To Advancing Its Research And Development Effortsas Evidenced By Its $9 7 Million R&D Expenditure In 2023The Company Collaborates With Academic Institutions To Enhance Its Clinical Development And Validate Its Therapeutic Approaches
